# Newly HIV-Infected Gay, Bisexual and other Men Who Have Sex With Men (MSM) in Vancouver, British Columbia: Preliminary Findings of the Momentum Health Study

NJ Lachowsky<sup>1,2</sup> (nlachowsky@cfenet.ubc.ca), K Stephenson<sup>3</sup>, A Rich<sup>1</sup>, A Lal<sup>1</sup>, Z Cui<sup>1</sup>, G Colley<sup>1</sup>, P Sereda<sup>1</sup>, J Brown<sup>4</sup>, J Jollimore<sup>5</sup>, D Hall<sup>3</sup>, JSG Montaner<sup>1</sup>, EA Roth<sup>4,5</sup>, RS Hogg<sup>1,6</sup>, DM Moore<sup>1,2</sup>

1 British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada 2 Faculty of Medicine, University of British Columbia, Vancouver, Canada 3 Vancouver Coastal Health, Vancouver, Canada

4 Youth Co Society for HIV and Hep C, Vancouver, Canada5 Health Initiative for Me, Vancouver, Canada6 Department of Anthropology, University of Victoria, Victoria, Canada

7 Centre for Addictions Research BC, Victoria, Canada 8 Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada

#### **Background**

- In Canada, gay and other men who have sex with men (MSM) have an incidence rate 71 times greater than non-MSM (PHAC, 2014)
- In British Columbia, the number of new HIV diagnoses among MSM has remained relatively stable for the past decade (~140-180 / year)
- We measured HIV incidence among participants in a prospective cohort of MSM in Vancouver, British Columbia and explored characteristics associated with HIV seroconversion.

#### **Methods**

**Study Protocol & Participants:** The <u>Momentum Health Study</u> is a prospective longitudinal bio-behavioural study of gay and other MSM aged 16+ in <u>Metro Vancouver</u> recruited using <u>respondent-driven sampling</u> from February 2012 to February 2015.

**Data:** Participants complete in-person study visits every 6 months that last ~90 minutes and include a <u>computer-assisted self-interview (CASI)</u> on demographics, sexual behaviour, substance use, and psychosocial attributes, and a subsequent nurse visit with rapid point-of-care HIV testing and for biological specimen collection for HIV and syphilis serology.

**Outcome:** Seroconvertors were participants who tested HIV-negative at baseline and HIV-positive at a subsequent study visit or another testing source between visits. Participants report their data of HIV diagnosis, which was used to calculate a prospective HIV incidence rate. We also examine participants who self-reported being HIV-negative at baseline, but tested HIV-positive during the clinical portion of their study visit. A retrospective HIV incidence is calculated using the date of their last reported HIV-negative test result.

**Explanatory Variables:** Behavioural data are drawn from their most recently completed questionnaire prior to HIV diagnosis, or their last completed questionnaire for participants who remained HIV-negative. Explanatory factors include demographics, sexual behaviour, STI testing and diagnosis history, substance use, and various psychosocial scales:

- HAART Optimism (Van de Ven et al., 2000; study α=0.82)
- Sexual Sensation Seeking (Kalichman & Rompa, 1995; study α=0.82)
- Cognitive Escape (McKirnan et al., 2001; study α=0.88)
- Sexual Altruism Personal and Communal subscales (Nimmons & Folkman, 1999; study α=0.83 & 0.89, respectively)
- Self Esteem (Herek & Glunt, 1995; study  $\alpha$ =0.91)
- Hospital Anxiety and Depression subscales (Zigmond & Snaith, 1983; study α=0.85 & 0.81, respectively).

**Statistical Analysis:** Incidence rates were calculated both retrospectively and prospectively. The prospective estimates were further stratified by age (<30 years versus older). Descriptive statistics and univariate associations were prepared to compare HIV seroconvertors and those who remained HIV-negative using Poisson regression (p<0.05 was considered significant) with adjustments with different lengths of follow-up time. Incidence rate ratios are presented with 95% confidence intervals.

## Results (Incidence Rate)

- As of May 30<sup>th</sup>, 2015, 406 MSM who tested HIV-negative at baseline contributed 664 person-years of follow-up (mean=1.63 years/person).
- At baseline, 3 participants were diagnosed (of 518 with recent test data) that had self-identified as HIV-negative prior. The retrospective incidence rate was 0.58 per 100 person-years (95% CI: 0.19-1.78).
- During follow-up, 6 participants seroconverted. **The prospective** incidence rate was **0.90** per **100** person-years (95% CI: 0.41-2.01).
- The HIV incidence for younger MSM (aged <30 years) was 1.80 per 100 person-years (95% CI: 0.75-4.32) and was marginally statistically higher than older MSM (p=0.077; RR=6.92, 95% CI: 0.81-58.94)

#### Results (Seroconversion Factors)

 Table 1 shows descriptive statistics of seroconvertors (n=6) compared with those who remain HIV-negative (n=400), including a p-value and univariable measure of association (if possible). **Bold** factors are statistically significant.

TABLE 1. Selected descriptive statistics and univariable associations

)8 60 66 11
60 66 11
60 66 11
66 11
11
92
56
35
01
)1
30
)2
)2
)7
26
001
36
66
01 01
.,.
01 001
01
01 001
<b>01</b> <b>001</b> 07
01 001 07 01
01 001 07 01 65
01 001 07 01 65
01 001 07 01 65 66
0 0 0 0 0 0 0

NB: **Bolded** text indicates p<0.05; RR=incidence rate ratio; \*CAI=condomless anal intercourse; P6M=past 6 months

## **Conclusions**

- 5 of 6 recent HIV seroconvertors in our study were aged <30, which differs from provincial surveillance reports, where approximately 30% of new diagnoses among MSM in 2013 were in this age range.
- Men who seroconverted reported frequent partner change, greater sensation seeking, and greater rates of anal intercourse who appeared to understand that they were at higher risk for HIV acquisition.
- These men were more likely to attend group sex events, have used crystal methamphetamine, report a greater number of older sexual partners, and report condomless anal intercourse with an HIV-positive partner.
- HIV prevention programs should further target such individuals.

## Acknowledgements

This work was supported by the Canadian Institutes for Health Research [107544]; National Institutes for Health, National Institute for Drug Abuse [R01DA031055] and Health Canada. We thank our community colleagues at the Health Initiative for Men, YouthCO HIV & HepC Society of BC, and Positive Living BC for their support. We also thank the research participants for sharing their important data with the Momentum Health Study. DMM is supported by a Scholar Award from the Michael Smith Foundation for Health Research.

I have no conflicts of interest.





BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS























